Table 2. Treatment Resistance, State Illness Severity and Current Medication.
No patients had psychotic symptoms and quetiapine was prescribed as an augmentation agent for antidepressants [71], similar to the long established use of lithium, L-tryptophan and tri-iodothyronine in treatment resistant depression. No obvious relationships between current medication and treatment resistance/state illness severity were present. ‘mg’ indicates total dose per day, ‘mcg’ total micrograms per day.
| HDRS17 | Primary Anti-depressant | Secondary Anti-depressant | Primary Augmentation | Secondary Augmentation | Anti-psychotic Medication |
|---|---|---|---|---|---|
| 21 | fluoxetine (60 mg) | mirtazapine (45 mg) | lithium (900 mg) | ||
| 4 | venlafaxine (525 mg) | mirtazapine (45 mg) | |||
| 11 | sertraline (100 mg) | trazodone (200 mg) | quetiapine (300 mg) | ||
| 8 | venlafaxine (300 mg) | lithium (200 mg) | |||
| 16 | phenelzine (60 mg) | L-Tryptophan (3000 mg) | lithium (1000 mg) | quetiapine (75 mg) | |
| 29 | chlorpromazine (150 mg) | ||||
| 19 | venlafaxine (300 mg) | L-Tryptophan (6000 mg) | |||
| 21 | fluoxetine (100 mg) | trazodone (150 mg) | |||
| 18 | venlafaxine (525 mg) | trazodone (150 mg) | |||
| 18 | isocarboxazid (70 mg) | ||||
| 24 | sertraline (300 mg) | trazodone (300 mg) | tri-iodothyronine (20 mcg) | quetiapine (800 mg) | |
| 12 | venlafaxine (75 mg) | ||||
| 14 | tranylcypromine (70 mg) | ||||
| 19 | isocarboxazid (40 mg) | quetiapine (75 mg) | |||
| 13 | sertraline (100 mg) | quetiapine (100 mg) | |||
| 16 | sertraline (200 mg) | quetiapine (300 mg) | |||
| 14 | venlafaxine (300 mg) | quetiapine (200 mg) | |||
| 18 | venlafaxine (225 mg) | ||||
| 14 | citalopram (60 mg) | ||||
| 13 | citalopram (10 mg) |